Modulating testosterone pathway: A new strategy to tackle male skin aging?

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 351-361

  Bernard, Philippe ^a   Scior, Thomas ^b   Do, Quoc Tuan ^a  

^a Greenpharma SA   (France)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Dermopharmacy; Honokiol; Man cosmetics; Reverse pharmacognosy; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANTIAGING AGENT; AROMATASE; AROMATASE INHIBITOR; DERMATOLOGICAL AGENT; DIIODOTHYRONINE; ESTROGEN; FINASTERIDE; HONOKIOL; LETROZOLE; MINOXIDIL; NATURAL PRODUCT; PHLORETIN; PLACEBO; PRASTERONE; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANDROPAUSE; ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; COMPARATIVE STUDY; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DRUG DATABASE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IC 50; IN VITRO STUDY; LABORATORY DEVICE; MALE; MALE TYPE ALOPECIA; MEN'S HEALTH; MOLECULAR MODEL; NORMAL HUMAN; ONSET AGE; PHARMACOGNOSY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; RELIABILITY; SKIN DENSITY; SKIN ELASTICITY; SKIN MOISTURE; SKINFOLD THICKNESS; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM; TESTOSTERONE SYNTHESIS; TESTOSTERONE TISSUE LEVEL; TISSUE LEVEL; VALIDATION PROCESS; WRINKLE;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ANIMALS; AROMATASE; BIPHENYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; HUMANS; LIGNANS; MAGNOLIA; MALE; MIDDLE AGED; SKIN AGING; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 84872303532     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S34034     Document Type: Article

References (61)

1. Phillips TJ, Demircay Z, Sahu M. Hormonal effects on skin aging. Clin Geriatr Med. 2001;17(4):661-672.
2. Wespes E, Schulman CC. Male andropause: myth, reality, and treatment. Int J Impot Res. 2002;14 Suppl 1:S93-S98.
3. Zouboulis CC. Intrinsic skin aging. A critical appraisal of the role of hormones. Hautarzt. 2003;54(9):825-832.
4. Theodoraki A, Bouloux PM. Testosterone therapy in men. Menopause Int. 2009;15(2):87-92.
5. Beg S, Al-Khoury L, Cunningham GR. Testosterone replacement in men. Curr Opin Endocrinol Diabetes Obes. 2008;15(4):364-370.
6. Diver MJ. Laboratory measurement of testosterone. Front Horm Res. 2009;37:21-31.
7. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab. 2009;5(2):113-121.
8. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302.
9. Cilotti A, Falchetti A. Male osteoporosis and androgenic therapy: from testosterone to SARMs. Clin Cases Miner Bone Metab. 2009;6(3):229-233.
10. Abdullah F, Rashid RM. Alopecia: botanical approaches in review. J Drugs Dermatol. 2010;9(5):537-541.
11. Shapiro J, Price VH. Hair regrowth. Therapeutic agents. Dermatol Clin. 1998;16(2):341-356.
12. Lee WJ, Jung HD, Chi SG, etal. Effect of dihydrotestosterone on the upregulation of inflammatory cytokines in cultured sebocytes. Arch Dermatol Res. 2010;302(6):429-433.
13. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol. 2004;22(5):360-366.
14. Larsen PR, Williams RL, editors. Williams Textbook of Endocrinology. Philadelphia: WB Saunders; 2003.
15. Sator PG, Schmidt JB, Sator MO, Huber JC, Hönigsmann H. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas. 2001;39(1):43-55.
16. Lawrentschuk N, Fleshner N. Severe irritant contact dermatitis causing skin ulceration secondary to a testosterone patch. Scientific World Journal. 2009;20:333-338.
17. Inui S, Itami S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2011;61(1):1-6.
18. Bader U, Trüeb RM. Androgenetic alopecia in the man. Ther Umsch. 2002;59(5):211-216.
19. Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37(8-9):981-990.
20. Hoffmann R. Hormonal interaction and hair growth. Ann Dermatol Venereol. 2002;129(5 Pt 2):787-792.
21. Lo YC, Teng CM, Chen CF, Chen CC, Hong CY. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol. 1994;47(3):549-553.
22. Maruyama Y, Kuribara H. Overview of the pharmacological features of honokiol. CNS Drug Rev. 2000;6(1):35-44.
23. Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur J Pharmacol. 2003;475(1-3):19-27.
24. Bai X, Cerimele F, Ushio-Fukai M, etal. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem. 2003;278(37):35501-35507.
25. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res. 2006;4(9):621-633.
26. Lee B, Kim CH, Moon SK. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett. 2006;580(22):5177-5184.
27. Battle TE, Arbiser J, Frank DA. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood. 2005;106(2):690-697.
28. Hahm ER, Singh SV. Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity. Mol Cancer Ther. 2007;6(10):2686-2695.
29. Bruneton J. Pharmacognosie, Phytochimie, Plantes Médicinales. Paris, France: Lavoisier; 1993: viii.
30. Do QT, Bernard P. Pharmacognosy and reverse pharmacognosy: a new concept for accelerating natural drug discovery. IDrugs. 2004;7(11):1017-1027.
31. Harrigan GG, Brackett DJ, Boros LG. Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. Mini Rev Med Chem. 2005;5(1):13-20.
32. Scior T, Bernard P, Medina-Franco JL, Maggiora GM. Large compound databases for structure-activity relationships studies in drug discovery. Mini Rev Med Chem. 2007;7(8):851-860.
33. Bernard P, Scior T, Didier B, Hibert M, Berthon JY. Ethnopharmacology and bioinformatic combination for leads discovery: application to phospholipase A(2) inhibitors. Phytochemistry. 2001;58(6):865-874.
34. Berman HM, Westbrook J, Feng Z, etal. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-242.
35. Scior T, Wahab HA. Structure prediction of proteins with very low homology: A comprehensive introduction and a case study on aminopeptidase. In: Kaplan SP, editor. Drug Design Research Perspectives. New York, NY: Nova Science Publishers; 2007:675-708.
36. Grishkovskaya I, Avvakumov GV, Sklenar G, Dales D, Hammond GL, Muller YA. Crystal structure of human sex hormone-binding globulin: steroid transport by a laminin G-like domain. EMBO J. 2000;19(4):504-512.
37. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Journal Nature. 2009;457(7226):219-223.
38. Faucher F, Cantin L, Luu-The V, Labrie F, Breton R. Crystal structures of human Delta4-3-ketosteroid 5beta-reductase (AKR1D1) reveal the presence of an alternative binding site responsible for substrate inhibition. Biochemistry. 2008;47(51):13537-13546.
39. SYBYL, Tripos Inc. 1699 South Hanley Road, St Louis, MO, 63144, USA.
40. Scior T, Bender A, Tresadern G, etal. Recognizing pitfalls in virtual screening: a critical review. J Chem Inf Model. April 6, 2012. [Epub ahead of print.]
41. Purba HS, Bhatnagar AS. A comparison of methods measuring aromatase activity in human placenta and rat ovary. J Enzyme Inhib. 1990;4(2):169-178.
42. Reichert W, Hartmann RW, Jose J. Stable expression of the human 5alpha-reductase isoenzymes type I and type II in HEK293cells to identify dual and selective inhibitors. J Enzyme Inhib. 2001;16(1):47-53.
43. Délos S, Iehlé C, Martin PM, Raynaud JP. Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145cells and expressed in insect cells. J Steroid Biochem Mol Biol. 1994;48(4):347-352.
44. Boudon C, Lobaccaro JM, Lumbroso S, etal. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates-effect of finasteride (Proscar), a 5 alpha-reductase inhibitor. Cell Mol Biol (Noisy-le-grand). 1995;41(8):1007-1015.
45. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-275.
46. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010;38(Database issue):D355-D360.
47. Seralini G, Moslemi S. Aromatase inhibitors: past, present and future. Mol Cell Endocrinol. 2001;178(1-2):117-131.
48. Occhiato EG, Guarna A, Danza G, Serio M. Selective non-steroidal inhibitors of 5 alpha-reductase type 1. J Steroid Biochem Mol Biol. 2004;88(1):1-16.
49. Kahn SM, Hryb DJ, Nakhla AM, Romas NA, Rosner W. Sex hormone-binding globulin is synthesized in target cells. J Endocrinol. 2002;175(1):113-120.
50. Makrantonaki E, Schoenknecht P, Hossini AM, etal. Skin and brain age together: The role of hormones in the ageing process. Exp Gerontol. 2010;45(10):801-813.
51. Bolognia JL. Aging skin. Am J Med. 1995;98(1A):99S-103S.
52. Roskos KV, Maibach HI, Guy RH. The effect of aging on percutaneous absorption in man. J Pharmacokinet Biopharm. 1989;17(6):617-630.
53. Schreiber G, Ziemer M. The aging male-diagnosis and therapy of late-onset hypogonadism. J Dtsch Dermatol Ges. 2008;6(4):273-279.
54. Matsumoto AM. Physical, metabolic and endocrine correlates of male aging. Filicori M, editor. Endocrine Basis of Reproductive Function, Proceedings of the Conference; January 20-22, 2000; Tampa, FL, US: 525-535.
55. Baulieu EE, Thomas G, Legrain S, etal. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000;97(8):4279-4284.
56. Calof OM, Singh AB, Lee ML, etal. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Med Sci. 2005;60(11):1451-1457.
57. Wright ET, McGillis TJ, Sobel H. Action of testosterone on the skin of aging male subjects. Dermatologica. 1970;140(2):124-128.
58. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007;39(2):85-95.
59. El-Alfy M, Labrie F, Azzi L, inventors; Endorech Inc, assignee. Use of androgens to reduce the likelihood of acquiring or to treat skin aging. United States patent US 2006/0178352A1. November 1, 2005.
60. Sergeev PV, Ukhina TV, Shimanovskii NL. Effects of hormones on phospholipase A2 activity in rat skin. Pharmacology and Toxicology. 2000;129(1):60-62.
61. Ebling FJ. Hair. J Invest Dermatol. 1976;67(1):98-105.